vs
Side-by-side financial comparison of Virgin Galactic Holdings, Inc (SPCE) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $4.2M, roughly 1.3× Virgin Galactic Holdings, Inc). Taysha Gene Therapies, Inc. runs the higher net margin — -507.8% vs -2222.2%, a 1714.4% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs 125.5%).
Virgin Galactic Holdings, Inc. is a British-American spaceflight company founded by Richard Branson and the Virgin Group conglomerate, which retains an 11.9% stake through Virgin Investments Limited.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
SPCE vs TSHA — Head-to-Head
Income Statement — Q2 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.2M | $5.5M |
| Net Profit | $-93.8M | $-27.9M |
| Gross Margin | -546.6% | — |
| Operating Margin | -2412.1% | -516.0% |
| Net Margin | -2222.2% | -507.8% |
| Revenue YoY | 125.5% | 171.3% |
| Net Profit YoY | 30.2% | -48.3% |
| EPS (diluted) | $-4.36 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $5.5M | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $2.0M | ||
| Q1 25 | — | $2.3M | ||
| Q4 24 | — | $2.0M | ||
| Q3 24 | — | $1.8M | ||
| Q2 24 | $4.2M | $1.1M | ||
| Q1 24 | $2.0M | $3.4M |
| Q4 25 | — | $-27.9M | ||
| Q3 25 | — | $-32.7M | ||
| Q2 25 | — | $-26.9M | ||
| Q1 25 | — | $-21.5M | ||
| Q4 24 | — | $-18.8M | ||
| Q3 24 | — | $-25.5M | ||
| Q2 24 | $-93.8M | $-20.9M | ||
| Q1 24 | $-102.0M | $-24.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -546.6% | — | ||
| Q1 24 | -1038.1% | — |
| Q4 25 | — | -516.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1347.1% | ||
| Q1 25 | — | -930.5% | ||
| Q4 24 | — | -985.8% | ||
| Q3 24 | — | -1448.4% | ||
| Q2 24 | -2412.1% | -1915.4% | ||
| Q1 24 | -5599.9% | -713.3% |
| Q4 25 | — | -507.8% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1353.6% | ||
| Q1 25 | — | -935.2% | ||
| Q4 24 | — | -929.0% | ||
| Q3 24 | — | -1427.5% | ||
| Q2 24 | -2222.2% | -1882.0% | ||
| Q1 24 | -5139.1% | -705.4% |
| Q4 25 | — | $-0.08 | ||
| Q3 25 | — | $-0.09 | ||
| Q2 25 | — | $-0.09 | ||
| Q1 25 | — | $-0.08 | ||
| Q4 24 | — | $-0.07 | ||
| Q3 24 | — | $-0.10 | ||
| Q2 24 | $-4.36 | $-0.09 | ||
| Q1 24 | $-5.10 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $775.7M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $394.8M | $246.9M |
| Total Assets | $1.1B | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $319.8M | ||
| Q3 25 | — | $297.3M | ||
| Q2 25 | — | $312.8M | ||
| Q1 25 | — | $116.6M | ||
| Q4 24 | — | $139.0M | ||
| Q3 24 | — | $157.7M | ||
| Q2 24 | $775.7M | $172.7M | ||
| Q1 24 | $765.2M | $124.0M |
| Q4 25 | — | $246.9M | ||
| Q3 25 | — | $219.0M | ||
| Q2 25 | — | $248.7M | ||
| Q1 25 | — | $55.1M | ||
| Q4 24 | — | $71.5M | ||
| Q3 24 | — | $88.8M | ||
| Q2 24 | $394.8M | $108.9M | ||
| Q1 24 | $417.6M | $53.8M |
| Q4 25 | — | $343.3M | ||
| Q3 25 | — | $316.6M | ||
| Q2 25 | — | $333.3M | ||
| Q1 25 | — | $138.4M | ||
| Q4 24 | — | $160.4M | ||
| Q3 24 | — | $180.2M | ||
| Q2 24 | $1.1B | $200.4M | ||
| Q1 24 | $1.1B | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-79.1M | $-26.7M |
| Free Cash FlowOCF − Capex | $-113.5M | — |
| FCF MarginFCF / Revenue | -2690.7% | — |
| Capex IntensityCapex / Revenue | 815.5% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-458.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-24.2M | ||
| Q2 25 | — | $-20.2M | ||
| Q1 25 | — | $-22.0M | ||
| Q4 24 | — | $-18.3M | ||
| Q3 24 | — | $-21.6M | ||
| Q2 24 | $-79.1M | $-21.5M | ||
| Q1 24 | $-113.2M | $-19.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-24.3M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-18.3M | ||
| Q3 24 | — | $-21.6M | ||
| Q2 24 | $-113.5M | $-21.7M | ||
| Q1 24 | $-126.3M | $-19.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -905.5% | ||
| Q3 24 | — | -1210.9% | ||
| Q2 24 | -2690.7% | -1951.9% | ||
| Q1 24 | -6362.8% | -584.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | 815.5% | 18.1% | ||
| Q1 24 | 658.5% | 4.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
